



MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Corporate Identity No. L24111UR1986PLC015895

Regd. Office: Upper Kesalton, Tallital, Nainital- 263 001, Uttarakhand, Tel: 9871862796

MPL/33/QTR-1/2019-20 W: www.mescopharma.com E-mail: nsparameswaran@mescoindia.com 12th August, 2019

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

Scrip ID: MESPHAR-B

Scrip Code: 500274

Sub: Un-Audited Financial Results for the Quarter ended 30th June, 2019

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Un-Audited Financial Results for the Quarter ended 30th June, 2019.

M/s. Sangram Paul & Co., Chartered Accountants, Statutory Auditors of the Company has issued the Limited Review Report


The Board meeting commenced at 1.45 P.M. and concluded at 02.20p.m.

A Copy of the said results together with Limited Review Report is enclosed herewith. These results are also being made available on the website of the Company at <http://www.mideastindia ltd.com/>

This is for your information and records.

Thanking You,

Yours Faithfully,
For **Mesco Pharmaceuticals Limited**


Sameer Singh
(Managing Director)
DIN: 06862254



MESCO PHARMACEUTICALS LTD

CIN : L24111UR1986PLC015895

REGD.OFFICE : UPPER KESALTON, TALLITAL, NAINITAL-263 001, UTTARAKHAND

Tel. :011-41587085, E-mail : nsparameswaran@mescosteel.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019

(In Rs.)

S. No.	PARTICULARS	Quarter Ended			Year Ended
		30.06.2019	31.03.2019	30.06.2018	31.03.2019
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Income from Operations				
	(a) Net Sales/ Income from operations	-	-	-	-
	(b) Other Income	-	-	-	-
	Total Income from Operations (net)	-	-	-	-
2	Expenses				
	(a) Cost of Material Consumed	-	-	-	-
	(b) Change in Inventories of finished goods and work in progress	-	-	-	-
	(c) Employees Benefits Expenses	-	-	-	-
	(d) Depreciation and Amortisation expenses	-	-	-	-
	(e) Finance Cost	-	-	-	-
	(f) Other Expenses	854,355.00	181,352.83	299,200.00	4,098,033
	Total Expenses	854,355.00	181,352.83	299,200.00	4,098,032.83
3	Profit/(Loss) Before Exceptional items and Tax Finance Costs & Exceptional Items (1-2)	(854,355.00)	(181,352.83)	(299,200.00)	(4,098,032.83)
	Exceptional Items	-	-	-	-
4	Profit/(Loss) before Tax	(854,355.00)	(181,352.83)	(299,200.00)	(4,098,032.83)
	(a) Current Tax	-	-	-	-
	(b) Deferred Tax	-	-	-	-
	(c) Tax expense relating to Earlier years	-	-	-	-
7	Profit for the Period	(854,355.00)	(181,352.83)	(299,200.00)	(4,098,032.83)
	Other Comprehensive Income				
	If any	-	-	-	-
	Total Comprehensive Income for the Period	(854,355.00)	(181,352.83)	(299,200.00)	(4,098,032.83)
14	Paid up Equity Share Capital (Face value Rs.10/- per Equity Share)	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00
16	Earning per share (before and after extraordinary items) (Rs.10- each)				
	Basic (Rs.)	(0.04)	(0.01)	(0.01)	(0.20)
	Diluted (Rs.)	(0.04)	(0.01)	(0.01)	(0.20)

Notes :

- The above Results, have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective Board Meeting held on 12th August, 2019
- The Statutory Auditors of the Company have carried out Limited Review of the above Results.
- Figures for the previous period have been re-classified, re-grouped/ re-arranged wherever necessary.
- There were no manufacturing activities in the company during the period under consideration
- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1, 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder.

LACE: NEW DELHI

ATED : 12.08.2019



FOR AND ON BEHALF OF THE BOARD

For Mesco Pharmaceuticals Limited

Sameer Singh
Sameer Singh
Director

Sangram Paul & Co.

S.K. Paul. F.C.A

Chartered Accountant

Chartered Accountants

Plot No.-754/15, Jayadev Vihar, Bhubaneswar-751 013

Phone : 0674-2360863, Mob. : 9337116878

Review Report to MESCO PHARMACEUTICALS LIMITED

We have reviewed the accompanying statement of Unaudited financial results of **MESCO PHARMACEUTICALS LIMITED** for the quarter ended June 30, 2019 being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI circular CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with Indian Accounting Standard ("IND-AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No: CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sangram Paul & Co.

Chartered Accountants

Firm Registration No. 308001E

S.K. Paul

Proprietor

M. No.: - 013015



Date: 12th August, 2019

Place: New Delhi